OnKure Therapeutics, Inc.
$ 2.78
-3.47%
17 Oct - close price
- Market Cap 37,613,300 USD
- Current Price $ 2.78
- High / Low $ 2.95 / 2.72
- Stock P/E N/A
- Book Value 5.78
- EPS -4.46
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.71 %
- ROE -1.43 %
- 52 Week High 19.02
- 52 Week Low 1.70
About
OnKure Therapeutics, Inc. is an innovative biopharmaceutical firm dedicated to revolutionizing cancer treatment through the development of precision oncology therapies. Located in Boulder, Colorado, the company utilizes cutting-edge drug discovery platforms to target unmet needs in cancer care, showcasing a strong commitment to personalized medicine. With a diverse pipeline of targeted therapeutic candidates, OnKure is poised to make significant strides in enhancing patient outcomes and reshaping the landscape of oncology.
Analyst Target Price
$30.00
Quarterly Earnings
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-08-12 | 2025-05-06 | 2025-03-10 | 2024-11-07 | 2024-08-13 | 2024-05-07 | 2024-03-28 | 2023-11-13 | 2023-08-10 | 2023-05-11 | 2023-03-27 | 2022-11-08 |
| Reported EPS | -1.14 | -1.1863 | -1.37 | -0.86 | -1.6041 | -2.5212 | -7.0477 | -5.678 | -6.4639 | -6.034 | -5.5368 | -5.3098 |
| Estimated EPS | -1.248 | -1.38 | -0.87 | -0.9 | None | None | None | None | None | None | None | None |
| Surprise | 0.108 | 0.1937 | -0.5 | 0.04 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise Percentage | 8.6538% | 14.0362% | -57.4713% | 4.4444% | None% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OKUR
2025-02-24 13:00:00
--- Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of Directors --- BOSTON, Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Inhibikase Therapeutics, Inc.
